All Blogs

Sep 30, 2024

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...

Jun 10, 2025

Imagine a world where treatment options are as precise as a scalpel and as adaptable as a chameleon. Bispecific antibodies are paving the way for this future, bringing revolutionary advancements in oncology and various therapeutic fields. By harnessing the power of these dual-targeting agents, researchers are unloc...

Sep 27, 2024

On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...

Sep 27, 2024

Data from an integrated pooled analysis of finerenone across three Phase III trials involving heart failure, chronic kidney disease (CKD), and Type 2 diabetes (T2D) was presented at the 2024 European Association for the Study of Diabetes (EASD) Congress. This analysis was conducted with data from the FIDELIO-DKD2 a...

Sep 26, 2024

Vivos Therapeutics Received Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring On September 18, 2024, Vivos Therapeutics, Inc., a premier medical device and technology firm focused on innovative treatments for sleep-related breathing disorders (SRBDs), including obs...

Sep 25, 2024

Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men, affecting approximately 1 in 8 men in the United States during their lifetime. With nearly 288,000 new cases diagnosed each year, men must prioritize regular screenings and early detection...

Sep 24, 2024

FDA Greenlights Zevra Therapeutics’ MIPLYFFA for Niemann-Pick Disease Type C Zevra Therapeutics, Inc. has announced that the FDA has approved MIPLYFFA (arimoclomol) capsules as the first oral treatment for Niemann-Pick disease type C. Indicated for use alongside miglustat, MIPLYFFA is intended for both adult and...

Sep 23, 2024

Better late than never for FDA approval of the first subcutaneous PD-L1 inhibitor—Roche’s TECENTRIQ HYBREZA—after manufacturing delays disrupted the company’s initial launch plans last year. The FDA was originally set to decide on TECENTRIQ’s under-the-skin formulation in September, but Roche’s delivery technolo...

Sep 20, 2024

Artificial Intelligence (AI) is one of the most groundbreaking innovations of the 21st century, with applications spanning nearly every industry, including healthcare. In respiratory care, Artificial intelligence has the potential to enhance accuracy and efficiency while reducing costs. It can play a transformative...

Sep 20, 2024

NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (roughly 509,000 incident cases in 2019 [7MM: the US, EU4 and the UK, and Japan]). The real-world treatment trend depicts a significant shift towards targeted and immunotherapies (from only systemic therapies in the pa...